Pages

Sunday, January 1, 2023

Wall Street Analysts: No More Good Drilling Sites In The Bakken; Harold Hamm: "Here, Hold My Beer" -- CLR Bang Wells Update -- January 1, 2023

The CLR Bang wells are tracked here.

January 1, 2023: production data updated -

  • 38673, drl/A, CLR, Bang 8-4H, Cedar Coulee, 
PoolDateDaysBBLS OilRunsBBLS WaterMCF ProdMCF SoldVent/Flare
BAKKEN10-2022314388543954297864921848410592
BAKKEN9-20221416794166051116019724183771347
  •  38674, drl/A, CLR, Bang 7-4H1, Cedar Coulee,
PoolDateDaysBBLS OilRunsBBLS WaterMCF ProdMCF SoldVent/Flare
BAKKEN10-2022314013040198324384628545512557
BAKKEN9-2022131588815710134621480713975832
BAKKEN8-202210012264330433
  •  38675, drl/A, CLR, Bang 6-4H, Cedar Coulee,
PoolDateDaysBBLS OilRunsBBLS WaterMCF ProdMCF SoldVent/Flare
BAKKEN10-2022313493934994397333982939134479
BAKKEN9-2022121313412983149551419113390801
BAKKEN8-2022351651610125080508
  •  38610, 2,015, CLR, Bang FIU 14-4HSL, Cedar Coulee,
PoolDateDaysBBLS OilRunsBBLS WaterMCF ProdMCF SoldVent/Flare
BAKKEN10-2022315003049844189505240652128278
BAKKEN9-20223054048538042298555440541191321
BAKKEN8-2022354354319568860886
  •  38614, 1,631, CLR, Bang 13-4H1, Cedar Coulee,
PoolDateDaysBBLS OilRunsBBLS WaterMCF ProdMCF SoldVent/Flare
BAKKEN10-2022314436244587304165300552150639
BAKKEN9-20222530213298662219432686308421844
BAKKEN8-202226216219824730473
  •  38609, 1,974, CLR, Bang 12-4H, Cedar Coulee,
PoolDateDaysBBLS OilRunsBBLS WaterMCF ProdMCF SoldVent/Flare
BAKKEN10-2022315023250545200965301152158637
BAKKEN9-20222539286388351738843366409182448
BAKKEN8-2022156756710284580458
  • 38608, drl/A, CLR, Bang 11-4H1, Cedar Coulee, 
PoolDateDaysBBLS OilRunsBBLS WaterMCF ProdMCF SoldVent/Flare
BAKKEN10-2022314889149115332875892758000711
BAKKEN9-20222531210308522209031909301111798
BAKKEN8-2022224724711032970297

2023: India Overtakes China -- Population -- January 1, 2023

This year, 2023: India overtakes China as most populous nation. Link here.

  • China: down-slope
  • India: up-slope


New Variant: XBB.1.B -- January 1, 2023

CDC: omicron subvariant XBB.1.5 now accounts for 40.5 of all cases. Links everywhere.
  • has pushed out BQ.1 and BQ.1.1 as the number one subvariants

The XBB subvariant, from which XBB.1.5 descends, is a recombinant of two subvariants that descended from the BA.2 omicron subvariant. That means it carries genetic data from two versions of the coronavirus that originated from the BA.2 subvariant.
Regionally, XBB.1.5 now accounts for the majority of COVID-19 cases in the northeast, identified as causing 75 percent of cases in New England and in the New York tri-state area.
The omicron subvariants XBB and XBB.1 were first identified in India.
Some scientists, including Scripps Research Institute professor of molecular medicine Eric Topol, have put forward the possibility that XBB.1.5 could have mutated in New York.

Re-posting Covid update from December 15, 2022

*********************
The Atlantic Story On Covid

 Covid variants:

The Atlantic story was written before Evusheld was taken off the market. Today, CNBC reported that the FDA took Evushel (Eli Lilly) off the market leaving only one in this sector: bebteloovimab (AstraZeneca).

For the first couple of years of the coronavirus pandemic, the crisis was marked by a succession of variants that pummeled us one at a time.
The original virus rapidly gave way to D614G, before ceding the stage to Alpha, Delta, Omicron, and then Omicron’s many offshoots.
But as our next COVID winter looms, it seems that SARS-CoV-2 may be swapping its lead-antagonist approach for an ensemble cast: Several subvariants are now vying for top billing.
In the United States, BA.5—dominant since the end of spring—is slowly yielding to a slew of its siblings, among them BA.4.6, BF.7, BQ.1, and BQ.1.1; another subvariant, XBB, threatens to steal the spotlight from overseas.
Whether all of these will divvy up infections in the next few months, or whether they’ll be pushed aside by something new, is still anyone’s guess. Either way, the forecast looks a little grim.
None of the new variants will completely circumvent the full set of immune defenses that human bodies, schooled by vaccines or past infections, can launch. Yet all of them seem pretty good at dodging a hefty subset of our existing antibodies.For anyone who gets infected, such evasions could make the difference between asymptomatic and feeling pretty terrible. And for the subset of people who become sick enough to need clinical care, the consequences could get even worse.
Some of our best COVID treatments are made from single antibodies tailored to the virus, which may simply cease to work as SARS-CoV-2 switches up its form.
Past variants have already knocked out several such concoctions—among them, REGEN-COV, sotrovimab, and bamlanivimab/etesevimab—from the U.S. arsenal.
The only two left are bebtelovimab, a treatment for people who have already been infected, and Evusheld, a crucial supplement to vaccination for those who are moderately or severely immunocompromised; both are still deployed in hospitals countrywide.
But should another swarm of variants take over, these two lone antibody therapies could also be obsolete within months, if not weeks.
“It seems like the writing is on the wall,” says Erin McCreary, an infectious-disease pharmacist at the University of Pittsburgh Medical Center. “I live constantly low-key worried that I’m not going to have an active therapy for my patients, and I won’t be able to help them.”
All of this bodes poorly for this winter and beyond. In the near term, millions of immunocompromised people could be left without viable options either to keep SARS-CoV-2 at bay or to temper its blaze once an infection begins to burn. And that loss would set a troubling precedent for seasons to come. The business end of the virus “is now adapting so rapidly that I don’t know how it’s going to be possible for monoclonals to keep up,” says Jeanne Marrazzo, an infectious-disease physician at the University of Alabama at Birmingham. Experts may need to revamp the strategies they use to bring new therapies to market—or find themselves, once again, in a serious bind.
“I worry,” Marrazzo told me, “that we’re on a razor’s edge.”

 

Laser-Focused On Dividends -- January 1, 2023

************
The Leaderboard



*************
What Happened To Connie Chung?
Chung, a first generation American, the tenth of 10 children, broke barriers of her own. She became the first Asian and second woman to anchor a major network newscast, when in 1993 she became co-anchor of CBS Evening News
Connie Chung and husband Maury Povich own a newspaper, The Flathead Beacon in Montana, where they have a house.
They split their time between homes in New York, Florida and Montana.
Connie and I have had a residence in Montana for over twenty years. We felt that the community where we lived in the Flathead Valley deserved more in a daily newspaper than what they were getting,” Povich told Parade in 2018. “It has been honored as the best weekly newspaper and website in the state….We are very proud of the paper, especially in the climate in which print journalism is trying to stay alive and finding new ways to exist.”